Filing summary
Entity mismatch: The request identifies Avalo Therapeutics, Inc., but the supplied 10-Q is for Cerecor Inc., for the quarter ended September 30, 2017. The summary below reflects the filing text; verify the issuer and filing before relying on it.
Business context and reporting period
Cerecor was a pre-commercial biopharmaceutical company developing candidates for neurologic and psychiatric disorders. Its portfolio included CERC-301, CERC-611 and CERC-406. It had no approved products and no product-sale revenue. Results cover the three and nine months ended September 30, 2017, compared with the same periods in 2016.
Financial results and liquidity
| Metric | Q3 2017 | Nine months 2017 |
|---|---|---|
| Total revenue | $25.04 million | $25.58 million |
| Operating income | $21.92 million | $18.25 million |
| Net income | $18.72 million | $14.96 million |
| Net income per share, basic and diluted | $0.52 | $0.65 |
| Operating cash flow | Not separately provided for the quarter | $15.11 million |
- Nearly all 2017 revenue included a one-time $25 million license and other revenue payment from selling CERC-501 rights to Janssen; grant revenue was $37,592 in Q3 and $579,597 year to date. The company reported no commercial product revenue.
- Q3 research and development expense was $0.96 million, down from $4.58 million; general and administrative expense was $2.15 million, up from $1.70 million. The filing does not provide a clear gross-margin measure.
- Cash and cash equivalents were $23.96 million at September 30, 2017, plus $3.75 million held in escrow as a receivable. Net working capital was $23.3 million. Cash increased $18.83 million in the first nine months.
- Term debt was fully repaid in August 2017; no term debt remained at quarter-end. Total liabilities were $6.08 million, including $3.23 million of income taxes payable and $1.25 million of license obligations.
Material changes versus prior periods
- Q3 revenue rose from $321,497 in 2016, and nine-month revenue from $971,985, primarily because of the CERC-501 sale. Q3 net income compared with a $6.17 million loss in 2016; nine-month net income compared with a $14.83 million loss.
- Nine-month R&D expense fell to $2.41 million from $9.38 million, reflecting completed or reduced clinical work, including CERC-301 and CERC-501 trials. Nine-month G&A decreased to $4.92 million from $5.99 million.
- In August, Cerecor sold all CERC-501 rights to Janssen for $25 million gross proceeds; $3.75 million was placed in a 12-month escrow, and a further $20 million regulatory milestone was possible. Janssen assumed ongoing trials and future development and commercialization responsibilities.
- In April, the company received $5 million gross proceeds in an Armistice private placement. Armistice converted its preferred shares into 11.94 million common shares in July and held majority voting control afterward. Common shares outstanding were 26,054,857 at September 30.
Outlook, risks and unusual items
- Management expected September 30 cash to fund expenses through at least December 31, 2018, while also stating that substantial additional financing would be required to execute its strategy. The company expected continued operating losses and no near-term product revenue.
- Management cited potential equity or debt financings, collaborations, licensing, grants and strategic alternatives as funding sources, but gave no assurance they would be available on acceptable terms. Failure to obtain funding could delay, scale back or end development programs or operations.
- The $18.72 million Q3 profit and $14.96 million year-to-date profit were substantially driven by the CERC-501 transaction, not recurring product sales. The company recorded $3.23 million income tax expense and anticipated a Q4 tax benefit from expected operating losses.
- The $3.75 million escrow is subject to indemnification obligations; the additional $20 million milestone is contingent. The company reported up to approximately $1.2 million of future contract research and external-service obligations.
- The former CEO resigned in August 2017; Q3 G&A included severance accruals and higher legal fees related to the CERC-501 sale. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm that this Cerecor 2017 filing, rather than a filing for Avalo Therapeutics, is the intended source.
- Review the Janssen agreement for escrow release conditions, indemnification exposure and the terms and likelihood of the potential $20 million milestone.
- Assess the cash runway against continuing development costs, financing needs and management’s stated expectation of future losses.
- Verify potential dilution and control implications from Armistice’s share and warrant holdings and other outstanding warrants and equity awards.
- Review the completed Section 382 analysis and any resulting limits on use of tax-loss carryforwards; the filing says the analysis was ongoing.